C4 Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

c4therapeutics.com

C4 Therapeutics has not claimed their Profile.

1 of C4 Therapeutics's competitors have claimed theirs

Here’s why one competitor wins customers.

FI

We demonstrated our technology as a feasibility study

Work for C4 Therapeutics?

Compete with C4 Therapeutics?

Brief our analysts.

Get in front of tech buyers.

100% free.

No pay-to-play nonsense.

Work for C4 Therapeutics?

Brief our analysts.

Get in front of tech buyers.

100% free.

No pay-to-play nonsense.

You May Also Like

Amphista Therapeutics Logo
Amphista Therapeutics

Amphista Therapeutics is a biopharmaceutical company that creates cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease-causing proteins.

P
Pin Therapeutics

Pin Therapeutics is a pharmaceutical company that creates therapeutic products based on chemical biology-driven protein degradation, including PROTAC technology. The company aims to develop PROTAC compounds for oncology, neurodegenerative diseases, and cardiovascular indications based on disease-agnostic approaches.

F
FIMECS

FIMECS is a drug discovery biotech firm focused on developing protein degradation therapeutics for cancers and other difficult-to-treat diseases.

Arvinas Logo
Arvinas

Arvinas (NASDAQ: ARVN) is a pharmaceutical company focused on developing small molecules aimed at degrading disease-causing cellular proteins. The company is translating these protein degradation approaches into drugs for the treatment of cancer and other diseases. Many diseases are a result of "rogue," uncontrolled proteins, whose absence could bring great clinical benefit to patients.

Kymera Therapeutics Logo
Kymera Therapeutics

Kymera Therapeutics (NASDAQ: KYMR) is a biotechnology company that develops an approach to treating previously untreatable diseases. Kymera aims to accelerate drug discovery with an ability to target and degrade proteins and advance treatment options for patients.

Nurix Therapeutics Logo
Nurix Therapeutics

Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. The drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.